Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.
Analyst Ratings
This is a summary of recent recommendations for Tarsus Pharmaceuticals and Harrow, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tarsus Pharmaceuticals | 1 | 2 | 4 | 2 | 2.78 |
| Harrow | 2 | 1 | 8 | 0 | 2.55 |
Tarsus Pharmaceuticals currently has a consensus price target of $90.50, suggesting a potential upside of 9.35%. Harrow has a consensus price target of $69.43, suggesting a potential upside of 77.79%. Given Harrow’s higher probable upside, analysts clearly believe Harrow is more favorable than Tarsus Pharmaceuticals.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tarsus Pharmaceuticals | $451.36 million | 8.05 | -$66.42 million | ($1.09) | -75.93 |
| Harrow | $272.30 million | 5.38 | -$5.14 million | ($1.00) | -39.05 |
Harrow has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Harrow, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Tarsus Pharmaceuticals has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.
Insider & Institutional Ownership
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.8% of Harrow shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Tarsus Pharmaceuticals and Harrow’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tarsus Pharmaceuticals | -7.67% | -13.53% | -8.12% |
| Harrow | -13.51% | -38.00% | -3.37% |
Summary
Tarsus Pharmaceuticals beats Harrow on 8 of the 15 factors compared between the two stocks.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About Harrow
Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
